India has emerged as the leading vaccine producer in
the world, in terms of doses of vaccines produced, and has about ~
major vaccine manufacturing facilities across the country. Vaccines
manufactured in these facilities are offered in both national and
international market (over 150 countries). With over ~ million births
every year, the domestic market for vaccines in India is huge. The
country has been self sufficient in meeting the domestic needs, with
private sector responsible for providing a large part of the supply
needs. However, India lacks in coverage rate of basic vaccines.
The Indian domestic market for Universal Immunization Programme (UIP) alone is over ~ million doses. The R&D cost of UIP vaccines is minimal; however, the non-UIP vaccines involve technology licensing, R&D, infrastructure and operational costs. In addition, stringent regulatory requirements for the licensing of newer vaccines, add up to the cost.
More than ~% of all measles vaccines used globally are produced in India. Moreover, Indian firms are big suppliers to the UN agencies, accounting in between ~% and ~% of the vaccines purchased by organization every year. India has emerged as a major vaccine producer in recent times by focusing on geographical regions where vaccines are not funded by the UN or charitable organizations and strategic ties with UN and government agencies to supply vaccines at affordable prices.
The Indian pediatric market for vaccines has grown at a remarkable CAGR of ~% during the period FY’2011-FY’2016.
The growth was attributed to some crucial vaccines (polio, hepatitis B, MMR and BCG) manufactured by Indian companies constantly featured in WHO’s prequalified list coupled with the fact that Indian companies (Serum Institute of India, Bharat Biotech, Panacea Biotec) acted as major suppliers of vaccines to WHO, UNICEF, PATH and other UN agencies. The market for pediatric vaccines grew from INR ~ billion in FY’2011 to INR ~ billion in FY’2016.
Monovalent vaccines are meant to immunize against a single antigen or a single microorganism. A fact that large chunk of vaccines administered under the national immunization programme in the country are of the monovalent form, is the major factor which has resulted in high revenue contribution from the segment. This includes monovalent oral polio vaccine, BCG, measles, Hepatitis B and Hib. Some other commonly used monovalent vaccines include rotavirus vaccine and TT.
Topics Covered in the Report
https://www.kenresearch.com/healthcare/pharmaceuticals/india-pediatric-drug-vaccine-market/81319-91.html
Related Reports:
Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market
US Aesthetic Lasers and Energy Devices Market Outlook to 2020 - Aging Population and High Prevalence Rate of Obesity to Foster Future Growth
Qatar Wellness Market Outlook to 2020 - Rising Awareness about health & Fitness and Prevalence in Lifestyle Diseases will drive the Market
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
The Indian domestic market for Universal Immunization Programme (UIP) alone is over ~ million doses. The R&D cost of UIP vaccines is minimal; however, the non-UIP vaccines involve technology licensing, R&D, infrastructure and operational costs. In addition, stringent regulatory requirements for the licensing of newer vaccines, add up to the cost.
More than ~% of all measles vaccines used globally are produced in India. Moreover, Indian firms are big suppliers to the UN agencies, accounting in between ~% and ~% of the vaccines purchased by organization every year. India has emerged as a major vaccine producer in recent times by focusing on geographical regions where vaccines are not funded by the UN or charitable organizations and strategic ties with UN and government agencies to supply vaccines at affordable prices.
The Indian pediatric market for vaccines has grown at a remarkable CAGR of ~% during the period FY’2011-FY’2016.
The growth was attributed to some crucial vaccines (polio, hepatitis B, MMR and BCG) manufactured by Indian companies constantly featured in WHO’s prequalified list coupled with the fact that Indian companies (Serum Institute of India, Bharat Biotech, Panacea Biotec) acted as major suppliers of vaccines to WHO, UNICEF, PATH and other UN agencies. The market for pediatric vaccines grew from INR ~ billion in FY’2011 to INR ~ billion in FY’2016.
Monovalent vaccines are meant to immunize against a single antigen or a single microorganism. A fact that large chunk of vaccines administered under the national immunization programme in the country are of the monovalent form, is the major factor which has resulted in high revenue contribution from the segment. This includes monovalent oral polio vaccine, BCG, measles, Hepatitis B and Hib. Some other commonly used monovalent vaccines include rotavirus vaccine and TT.
Topics Covered in the Report
- Vaccines Market Growth India,
- Drug Pipeline Pediatric ,
- Pediatric tuberculosis drug Market,
- Number of Pediatrician Statistics,
- Drug Information Dosage Side Effects,
- Pediatric Vaccine Serum Institute of India,
- New Drug Launches India Pharma Sector,
https://www.kenresearch.com/healthcare/pharmaceuticals/india-pediatric-drug-vaccine-market/81319-91.html
Related Reports:
Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market
US Aesthetic Lasers and Energy Devices Market Outlook to 2020 - Aging Population and High Prevalence Rate of Obesity to Foster Future Growth
Qatar Wellness Market Outlook to 2020 - Rising Awareness about health & Fitness and Prevalence in Lifestyle Diseases will drive the Market
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
